ZLAB
Zai Lab LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.09B
P/E Ratio
—
EPS
$-1.70
Beta
0.84
52W High
$44.34
52W Low
$15.96
50-Day MA
$20.36
200-Day MA
$23.33
Dividend Yield
—
Profit Margin
-39.30%
Forward P/E
—
PEG Ratio
—
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Fundamentals
| Revenue (TTM) | $453.28M |
| Gross Profit (TTM) | $36.74M |
| EBITDA | $-227.01M |
| Operating Margin | -69.70% |
| Return on Equity | -24.20% |
| Return on Assets | -13.40% |
| Revenue/Share (TTM) | $4.11 |
| Book Value | $6.47 |
| Price-to-Book | 3.16 |
| Price-to-Sales (TTM) | 4.61 |
| EV/Revenue | 3.7 |
| EV/EBITDA | -2.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -6.50% |
| Shares Outstanding | $112.36M |
| Float | $979.08M |
| % Insiders | 2.09% |
| % Institutions | 29.20% |
Historical Volatility
HV 10-Day
64.77%
HV 20-Day
61.42%
HV 30-Day
63.90%
HV 60-Day
58.16%
HV Rank
72.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($33.78 target)
2
Strong Buy9
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026